Fig. 3: FOXA1 is critical for the HER2 targeting response and for proliferation in HER2+ cell lines.
From: FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036
a RNAseq was performed on SKBR-3 cells treated with DMSO or 300 nM lapatinib for 24 h after treatment with a non-targeting (NT) siRNA pool or FOXA1 siRNA pool. The log2 fold changes in response to lapatinib are plotted as the NT siRNA effect (x-axis) versus FOXA1 siRNA effect (y-axis) for kinases (blue) and transcription factors (orange). HER2 is indicated in red. Dots sizes are scaled relative to their expression level. b SKBR-3 cells were treated with siRNA as in (a), then DMSO or 300 nM lapatinib for 24 h, harvested and subjected to immunoblotting to detect the indicated proteins. ERK2 was used as a loading control. c SKBR-3 and BT474.m1 cells were transfected with a NT siRNA pool or siRNA pools targeting the indicated transcription factor (TF) and then treated with DMSO or 300 nM lapatinib for 8 days. Cell growth was quantified every two days and plotted as the proportion of day 0 cell count. Data are plotted as mean ± s.d. for six replicates.
